key: cord-0843386-masxz4yo
authors: Zuo, Tao; Zhan, Hui; Zhang, Fen; Liu, Qin; Tso, Eugene Y.K.; Lui, Grace C.Y.; Chen, Nan; Li, Amy; Lu, Wenqi; Chan, Francis K.L.; Chan, Paul K.S.; Ng, Siew C.
title: Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge
date: 2020-06-26
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.06.048
sha: ff4f73a0e97c91bcd789a37fc458ffe973fc1588
doc_id: 843386
cord_uid: masxz4yo

Abstract Backgroud & Aims SARS-CoV-2 infects intestinal cells, and might affect the intestinal microbiota. We investigated changes in the fecal fungal microbiomes (mycobiome) of patients with SARS-CoV-2 infection during hospitalization and upon recovery. Methods We performed deep shotgun metagenomic sequencing analysis of fecal samples from 30 patients with COVID-19 in Hong Kong, from February 5 through May 12, 2020. Fecal samples were collected 2 to 3 times per week from time of hospitalization until discharge. We compared fecal mycobiome compositions of patients with COVID-19 with those from 9 subjects with community-acquired pneumonia and 30 healthy individuals (controls). We assessed fecal mycobiome profiles throughout time of hospitalization until clearance of SARS-CoV-2 from nasopharyngeal samples. Results Patients with COVID-19 had significant alterations in their fecal mycobiomes compared with controls, characterized by enrichment of Candia albicans and a highly heterogeneous mycobiome configuration, at time of hospitalization. Although fecal mycobiomes of 22 patients with COVID-19 did not differ significantly from those of controls during times of hospitalization, 8 of 30 patients with COVID-19 had continued significant differences in fecal mycobiome composition, through the last sample collected. The diversity of the fecal mycobiome of the last sample collected from patients with COVID-19 was 2.5-fold higher than that of controls (P<.05). Samples collected at all timepoints from patients with COVID-19 had increased proportions of opportunistic fungal pathogens, Candida albicans, Candida auris, and Aspergillus flavus compared with controls. Two respiratory-associated fungal pathogens, Aspergillus flavus and Aspergillus niger, were detected in fecal samples from a subset of patients with COVID-19, even after clearance of SARS-CoV-2 from nasopharyngeal samples and resolution of respiratory symptoms. Conclusions In a pilot study, we found heterogeneous configurations of the fecal mycobiome, with enrichment of fungal pathogens from the genera Candida and Aspergillus, during hospitalization of 30 patients with COVID-19 compared with controls. Unstable gut mycobiomes and prolonged dysbiosis persisted in a subset of patients with COVID-19 up to 12 days after nasopharyngeal clearance of SARS-CoV-2. Studies are needed to determine whether alterations in intestinal fungi contribute to or result from SARS-CoV-2 infection, and the effects of these changes in disease progression.

COVID-19 is a disease caused by a novel coronavirus (SARS-CoV-2), which primarily affects the respiratory system. Patients with COVID-19 present with variable disease symptoms and severity, some can be severe resulting in hospitalization, respiratory failure, or even death 1 . A recent meta-analysis of 35 COVID-19 studies reported that the pooled prevalence of digestive symptoms was 15% and pooled prevalence of digestive system comorbidities was 4% 2 . Patients with GI involvement tended to have a poor disease course 2 .

In addition, SARS-CoV-2 virus was detected in the feces and anal swabs in patients with COVID-19 and can infect human intestinal epithelium [3] [4] [5] . Altogether these data suggest that the gastrointestinal (GI) tract is an important extra-pulmonary site for SARS-CoV-2 infection.

Bacterial and fungal infections are common complications of viral pneumonia which may influence disease course and clinical manifestations, especially in critically ill patients 6 .

However, data regarding bacterial or fungal co-infections in viral pneumonia led by coronavirus is lacking. Our recent study showed that the gut bacterial microbiome was significantly altered in patients with COVID-19 with a significant expansion of opportunistic pathogens in the gut, which was associated with disease severity and fecal SARS-CoV-2 shedding 7 . Beyond bacteria, the GI tract also harbors a large number of fungi, collectively known as the mycobiome. Intestinal fungi have been shown to be causally implicated in microbiome assembly and immune development 8 . Accumulating findings highlighted that the gut mycobiota can strongly influence the host immune system and this interaction is linked to bacteria activities 9, 10 . Recent observations of the direct and indirect effects of fungal microbiota on various GI diseases have stimulated further investigation of the mycobiota composition and ways of regulating its diversity 11 . Although the magnitude of the number of fungal cells is smaller than that of the bacterial microbiota, their impact on health is significant especially as a reservoir for blooms of pathogenic microbes when the host is immunocompromised and as a co-factor in driving severe infectious diseases. It is unclear if the gut mycobiome is also altered and whether fungal pathogens co-bloom in COVID-19 and underlie disease course.

In this pilot study, we hypothesize that the intestinal fungal microbiome (mycobiome) is altered in SARS-CoV-2 infection and COVID-19 is associated with blooms of certain fungi in the gut. We prospectively included 30 patients with COVID-19 ( Table 1, 

This prospective study involved 30 COVID-19 patients hospitalized with laboratoryconfirmed SARS-CoV-2 infection, nine patients hospitalized with community acquired pneumonia (pneumonia controls) and 30 healthy individuals (controls) ( Table 1) . Thirty hospitalized COVID-19 patients were admitted between February 16, 2020 and April 1, 2020 in Hong Kong, China, and were followed from hospital admission until discharge (Figure 1 ). patients were collected serially 2 to 3 times per week until discharge. This study was conducted in accordance with the Declaration of Helsinki.

Approximately 0.1g fecal sample was prewashed with 1 ml ddH 2 O and pelleted by centrifugation at 13,000×g for 1 min. The fecal DNA was subsequently extracted from the pellet using Maxwell® RSC PureFood GMO and Authentication Kit (Promega, Madison, Wisconsin) following manufacturer's instructions. Briefly, fecal pellet was added 1ml of CTAB buffer and vortexed for 30 seconds, then heating sample at 95°C for 5 minutes. After that, the samples were vortexed thoroughly with beads at maximum speed for 15 min. Then 40µl of proteinase K and 20µl of RNase A was added into sample and the mixture was Incubated at 70°C for 10 minutes. The supernatant was then obtained by centrifuging at 13,000×g for 5 min and was added in Maxwell® RSC machine for DNA extraction.

Extracted DNA was subject DNA libraries construction, completed through the processes of end repairing, adding A to tails, purification and PCR amplification, using Nextera DNA Flex Library Preparation kit (Illumina). Libraries were subsequently sequenced on our in-house sequencer Illumina Novaseq 6000 (150bp paired-end) at Center for microbiota research,

The Chinese University of Hong Kong.

Raw sequence reads were filtered and quality-trimmed using Trimmomatic v0.36 13 as follows: 1) Trimming low quality base (quality score < 20); 2) Removing reads shorter than 50bp; 3) removing sequencing adapters. Contaminating human reads were filtering using Kneaddata (Reference database: GRCh38 p12) with default parameters. Profiling of the fungal community was performed using MiCoP. The fungal abundance profile of each sample was expressed in relative abundance (%) among the fecal fungal community 14 .

Data on the relative abundance of fecal fungi was imported into R v3.5.1. Non-metric Multidimensional Scaling (NMDS) analyses were performed on all baseline fecal mycobiomes between groups, and serial fecal mycobiomes in each COVID-19 case during the disease course, based on Bray-Curtis dissimilarities using vegan package (v2.5-3). Differential fungal taxa between patients with COVID-19 (at baseline or across all time points during hospitalization) and healthy controls were identified using LefSE 15 .

A total of 30 patients hospitalized with COVID-19, 30 healthy controls, and nine patients hospitalized with community-acquired pneumonia were included (Table 1; Supplementary   Table 1 ). All patients with COVID-19 presented with respiratory symptoms and four also had diarrhea at presentation. To understand alterations of the gut mycobiome that underlies SARS-CoV-2 infection, we compared baseline fecal mycobiome composition (first time point of stool sampling after hospitalization) between patients with COVID-19, healthy controls and pneumonia controls. At the whole fungal community level, fecal mycobiome of healthy controls densely clustered together whereas that of patients with COVID-19 formed a substantially broader cluster significantly different from that of controls (PERMANOVA test, p=0.001, Figure 2A ). Fecal mycobiome was more heterogeneous across patients with COVID-19 than controls, as demonstrated by an approximately six-fold increase in interindividual mycobiome dissimilarity in patients with COVID-19 relative to controls (p<2.22e-16, Figure 2B ). Patients with community-acquired pneumonia also showed heterogeneous fecal mycobiome configurations (Figure 2B) , indicating that both community-acquired pneumonia and COVID-19-associated pneumonia were both associated with fungal dysbiosis in the gut. We next identified differential fungal species in fecal samples between patients with COVID-19 and healthy controls adjusting for antibiotics use and co-morbidities. We found that Candida albicans was significantly enriched in 6 of 30 (20%) patients with COVID-19 but was absent in healthy controls (FDR p=0.04, Figure 2C ). These data suggest that gut mycobiome was significantly altered in patients with COVID-19 with an increase in Candida species.

We investigated longitudinal dynamics of the gut mycobiome in COVID-19 over time of hospitalization and explored whether recovery from SAR-CoV-2 infection was associated with restoration of gut mycobiome to a community similar to that of healthy individuals. The 

We showed for the first time that the gut mycobiome was disturbed in patients with COVID-19. Patients hospitalized with SARS-CoV-2 infection showed more heterogeneous gut mycobiome configurations (higher inter-individual mycobiome dissimilarities) compared with healthy individuals. These data suggest that gut microbiota changes induced by SARS-CoV-2, might at least in part, be stochastic, therefore leading to transition from a stable to unstable microbial community state in COVID-19 18 . In line with our findings in patients with COVID-19, a highly heterogeneous assembly of microbial community in response to disease stressors have been reported in the gut of patients with inflammatory bowel disease 19 Candida albicans has been shown to impair holistic gut microbiome assembly in humans and mice 25, 26 . Moreover, gut colonization by Candida albicans aggravated inflammation in the gut and non-gut tissues 27, 28 . Aspergillus infections were recently reported in respiratory tract secretions and tracheal aspirates in patients with COVID-19 from two studies (detection rate of 10% and 20%, respectively, in cohorts from China and France) 29 Pneumonia is one of the leading infectious causes of death 34 . Fungal co-infections in the respiratory tract and alterations in the lung mycobiome have been reported in pneumonia and pulmonary diseases 17, 35, 36 . However, to our knowledge, changes in the gut mycobiome were not reported in patients with pneumonia to date. In the present study, we observed that patients with community-acquired pneumonia also showed a significant alteration in the gut mycobiome compared with healthy controls. Similar to patients with COVID-19, blooms of opportunistic fungal pathogens, Candida species and Aspergillus species, were also seen in patients with community-acquired pneumonia. In contrast, patients with community-acquired pneumonia showed more heterogeneous gut mycobiome configurations than patients with COVID-19, indicating that the gut mycobiome in community-acquired pneumonia may be more "dysbiotic" than that in COVID-19. This could in part relates to the use of antibiotics in these individuals. In addition, the diversity and richness of the gut mycobiome were both significantly lower in patients with COVID-19 than patients with community-acquired pneumonia. These data collectively suggest that patients with COVID-19 have a similar but less severe dysbiosis of gut mycobiome compared to patients with community-acquired pneumonia.

One limitation of this exploratory study is the modest sample size. Although assigning a causative relationship between COVID-19 and gut fungal dysbiosis requires larger validation studies, this pilot study presents the first to examine the influence of SARS-CoV-2 infection on gut mycobiome composition and dynamics. Stool collected after hospitalization for mycobiome analysis does not represent the bona fide baseline mycobiome at COVID-19 onset, nor the baseline mycobiome before disease onset. In addition, it is unclear whether blooms of gut fungi are a result of SARS-CoV-2 infection or of co-infection during hospitalization. The contribution of gut fungi in the pathogenesis and disease progression of COVID-19 is also unknown. Future studies should prospectively include asymptomatic SARS-CoV-2-infected subjects without hospitalization. In addition, patients with symptomatic SARS-CoV-2 infection should be followed from disease onset until after recovery to thoroughly delineate the role of gut fungi during SARS-CoV-2 infection and the effects of these changes in disease progression and long-term health.

In conclusion, our study provides evidence of numerous blooms of fungal species in the gut of COVID-19 patients. These data highlight an important role of gut mycobiome in COVID-19.

The effects of gut fungi in disease pathogenesis and long-term health after recovery from SARS-CoV-2 infection warrant further investigation. Between-group comparison was conducted by wilcoxon rank sum test. patients over time of hospitalization. "CoV" denotes patient with COVID-19. "Controls" denotes healthy controls (n=30). "Pneumonia" denotes patient controls with pneumonia (n=9). "Day0" denotes baseline date when the first stool was collected after hospitalization; the following time points starting with 'Day' represent days since baseline stool collection.

"throat swab -ve" indicates the first negative result for SARS-CoV-2 virus in two consecutive negative nasopharyngeal/throat/pooled swab tests, upon which patient was then discharged. 

Travel to Wuhan City 0 (0%) 0 (0%)

Travel to other cities of Hubei province 1 (7%) 0 (0%)

Contact with person with COVID19 9 (30%) 0 (0%)

Have family cluster outbreak 4 (13%) 0 (0%) 

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

Virological assessment of hospitalized patients with COVID-2019

Evidence for gastrointestinal infection of SARS-CoV-2

Infection of bat and human intestinal organoids by SARS-CoV-2

Bacterial and fungal infections in COVID-19 patients: A matter of concern

Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization

Intestinal fungi are causally implicated in microbiome assembly and immune development in mice

Fungal microbiota in chronic airway inflammatory disease and emerging relationships with the host immune response

Activation of HIF-1α and LL-37 by commensal bacteria inhibits Candida albicans colonization

The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases

Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study

Trimmomatic: a flexible trimmer for Illumina sequence data

MiCoP: microbial community profiling method for detecting viral and fungal organisms in metagenomic samples

Metagenomic biomarker discovery and explanation

Clinical Interpretations and Therapeutic Significance of Isolating Aspergillus Species from Respiratory Specimens. A58. clinical studies in fungal infections

The clinical spectrum of pulmonary aspergillosis

Stress and stability: applying the Anna Karenina principle to animal microbiomes

Gut mucosal virome alterations in ulcerative colitis

Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America

Microbiome alterations in HIV infection a review

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)

Co-infections: potentially lethal and unexplored in COVID-19. The Lancet Microbe

Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection

Modulation of post-antibiotic bacterial community reassembly and host response by Candida albicans

Gut colonization by Candida albicans aggravates inflammation in the gut and extra-gut tissues in mice

Inflammation and gastrointestinal Candida colonization

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine

Clinical and virological data of the first cases of COVID-19 in Europe: a case series. The Lancet Infectious Diseases 2020. 31. van Arkel AL, Rijpstra TA, Belderbos HN, et al. COVID-19 Associated Pulmonary Aspergillosis

Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. The Lancet Respiratory Medicine

COVID-19 Associated Pulmonary Aspergillosis

Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study

The lung mycobiome: an emerging field of the human respiratory microbiome

Pathogenic Fungal Infection in the Lung

Author names in bold designate shared co-first authorship